Reportlinker.com

Reportlinker.com

March 26, 2008 18:49 ET

Key Challenges and Issues facing the World Organ And Tissue Transplantation Market

LONDON, UNITED KINGDOM--(Marketwire - March 26, 2008) - Reportlinker.com announces that a new market research report related to the Surgical material industry is available in its catalogue.

World Organ And Tissue Transplantation Market

This report analyzes the worldwide markets for Organ And Tissue Transplantation by Number of Procedures. The specific product segments analyzed for the global and other markets (except the US) by Organ Type are Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine. The US market has been specifically analyzed both by Organ & Tissue Transplantation market, and Bone Graft Transplantation market. The report analyzes the US market for Organ & Tissue Transplantation both by Organ Type (Heart, Kidneys, Liver, Pancreas, and Lungs) and by Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts). Bone Graft Transplantation market in the US is analyzed both by Graft Type (Autologous Graft, Allograft, and Other Materials); and by Application Type (General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2003 through 2012. The report profiles 77 companies including many key and niche players worldwide such as Abiomed Inc., Arbios Systems, Inc., CryoLife, Inc., Exactech, Inc., Fresenius Medical Care AG & Co. KGaA, Forticell Bioscience, Inc., Gambro AB, Genzyme Corporation, Jarvik Heart, Inc., LifeCell Corporation, Medtronic, Inc., MicroMed Cardiovascular, Inc., Organogenesis, Inc., SynCardia Systems, Terumo Corporation, Thoratec Corporation, Ventracor Limited, and WorldHeart Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Tissue and Organ Transplantation I-3

Bone Graft Transplantation I-4

Product Definitions I-4

Organ Transplantation I-4

Heart Transplantation I-4

Kidney Transplantation I-4

Liver Transplantation I-4

Pancreas Transplantation I-5

Small Intestine Transplantation I-5

Lungs I-5

Tissue Transplantation I-5

Corneal Transplantation I-5

Blood Stem Cell Transplantation I-5

Bone Marrow Transplantation I-6

Heart Valves Transplantation I-6

II. EXECUTIVE SUMMARY

1. Introduction II-1

2. Market Overview II-2

Current and Future Analysis II-2

Demand and Supply Imbalance II-2

Cardiac Arrest Death Patients - The Untapped Potential Donors II-2

Transplantation Expenses II-2

3. Market Trends II-4

Living Donor Organs on the Rise II-4

Combined Organ Transplantation - Gaining Attention II-4

Awareness Programs and Education to Address Organ shortage II-4

Increasing Consent Rates - A Key Factor II-4

Transplant Tourism - Creating Brighter Avenues II-4

Alliances to Play a Key Role II-5

Graying Population and Chronic Diseases Surge Need for Transplants II-5

Fetal Tissue for Bionic Devices - Assuming Importance II-5

4. Major Issues Impacting Transplantation Market II-7

Organ Rejection - A Major Barrier to Transplantation II-7

Scarcity of Donor Organs - A Stumbling Block in Organ Transplantation II-7

Other Issues for Organ Transplantation II-7

Ethical Concerns in Transplants II-7

Bioethical Issues Hindering Organ Donation Process II-8

Lack of Requisite Expertise - Hindering Implantation Process II-8

5. Product Overview II-9

Tissue and Organ Transplantation II-9

Organ Transplantation II-9

Heart Transplantation II-9

Heart Diseases and Disorders II-10

Post Operative Complications and Consequences of Heart Transplants II-10

Bleeding II-10

Infection II-10

Arrythymia II-10

Heart Attack II-10

Coronary Artery Disease II-11

Respiratory Dysfunction II-11

Renal Dysfunction II-11

Graft Rejection and Dysfunction II-11

Death II-11

Kidney Transplantation II-11

Kidney Disorders and Diseases II-12

Donor Evaluation II-12

Waiting List II-12

Surgery/Post-Operation II-12

Post-Operative Supervision and Issues II-12

Liver Transplantation II-13

Liver Disorders and Diseases II-13

Pancreas Transplantation II-14

Post Operative Complications and Consequences of Pancreas Transplants II-14

Small Intestine Transplantation II-15

Intestine Disorders and Diseases II-15

Heart-and-Lung Transplantation II-15

Lung Transplantation II-15

Lung Diseases and Disorders II-16

Lung Patients Survival Statistics II-16

Tissue Transplantation II-16

Types of Grafts II-16

Autograft II-16

Allograft / Homograft II-16

Transplant Tolerance II-17

Isograft II-17

Xenograft II-17

Corneal Transplantation II-18

Penetrating Keratoplasty II-18

Lamellar (Non-Penetrating) Keratoplasty II-18

Aftercare II-19

Risks Associated with Corneal Transplants II-19

Transplantation Outcomes II-19

Morbidity and Mortality Rates II-19

Alternatives II-19

Blood Stem Cells II-20

Peripheral Blood Stem Cell Transplant II-20

Umbilical Cord Blood Stem Cell Transplant II-20

Bone Marrow and Hematopoietic Stem Cells II-20

Bone and Tissue Transplantation II-20

Bone Marrow Transplants II-21

Stem Cell Therapy II-21

Human Heart Valves II-22

Atrioventricular Valves II-22

Mitral Valve II-22

Tricuspid Valve II-22

Semilunar Valves II-22

Aortic Valve II-22

Pulmonic Valve II-23

Pathology of Valves II-23

Prosthetic Heart Valves II-23

Prosthetic Mechanical Valve II-23

Advantages II-24

Disadvantages II-24

Prosthetic Biologic Valve II-24

Advantages II-24

Disadvantages II-25

Fetal Cells II-25

Fetal Tissue for Transplantation II-25

Storage Duration Time II-25

Storage Time Period for Organs and Tissues II-26

Cold Ischemia Time II-26

Transplantation Immunology II-26

Acute Cellular Rejection II-26

Chronic Rejection II-26

Post Transplant Observations II-27

Types of Donors II-27

Alive Donors II-27

Related Donors II-27

Good Samaritans II-27

Rewarded/Forced Donors II-27

Deceased Donors II-27

Directed / Allocated II-28

Organs and Tissues Transplanted by Type of Donor II-28

Organ/Tissue Donation and Eligibility Criteria II-28

Factors Considered for Matching Recipients to Donor Organs II-29

Testing II-29

Blood Typing II-29

Tissue Typing II-29

Histocompatibility - A Major Barrier for Organ Transplantation II-29

Transplantation - Safety Requirements II-30

Waiting List II-31

Active Waiting List Patients II-31

Inactive Waiting List Patients II-31

History II-31

Major Milestones in Organ Transplantation II-33

6. Artificial Organs II-34

Artificial Organs Revolutionize Medical Technology Industry II-34

Artificial Organs II-34

Categorization of Artificial Organs II-34

External Artificial Organs II-34

Internal or Implantable Artificial Devices II-35 Artificial Heart II-35

Total Artificial Heart (TAH) II-35

Ventricle Assist Device (VAD) II-35

Right Ventricular Assist Systems (RVAS) II-35

Left Ventricular Assist Systems (LVAS) II-35

Various Ventricle Assist Devices II-36

Artificial Kidney (Dialyzer) II-36

Limitations of Artificial Kidney II-37

Artificial Liver II-37

Various Liver Assist Devices II-37

Categorization of Liver Devices II-37

Mechanical Systems II-38

Bio-Artificial Systems II-38

Artificial Pancreas II-38

Artificial Lungs (Oxygenator) II-38

Types of Artificial Lung II-38

Artificial Cornea II-39

Keratoprostheses II-39

Tissue Engineered Corneas II-39

Artificial Skin/Skin Replacement Products II-39

AlloDerm Regenerative Tissue Matrix II-39

Apligraf II-39

Cymetra Micronized AlloDerm Tissue II-39

Dermagraft II-39

Epicel II-40

Integra Products II-40

OrCel II-40

TransCyte II-40

Core Competitive Factors II-40

Market Outlook for Artificial Organs II-41

7. Preservation Solutions & Immunosuppressant Drugs II-42

Organ Preservation Solutions II-42

Celsior Solution II-42

Collins Solution II-42

Euro Collins Solution II-42

Custodiol(R) HTK Solution II-42

Hypothermosol II-42

ViaSpan II-42

Immunosuppressant Drugs II-43

Antibody Products for Treatment of Organ Transplant Rejection II-43

Antithymocyte Globulin II-43

ATGAM II-43

Campath/MabCampath II-43

Thymoglobulin II-44

Therapeutic Antibody Products II-44

Antiproliferative Agents II-44

Azathioprine II-44

CellCept II-44

Certican II-44

Myfortic II-44

Calcineurin Inhibitors II-44

Cyclosporine II-45

Gengraf II-45

Neoral II-45

Pulminiq II-45

Tacrolimus II-45

Prograf II-45

TOR Inhibitors II-45

Side Effects of Immunosuppression Therapy II-46

Select Immunosuppressant Drug Players II-46

Astellas Pharma US, Inc., (USA) II-46

F.Hoffmann-La Roche Ltd (Switzerland) II-46

Novartis AG (Switzerland) II-46

Wyeth (USA) II-47

8. Regulatory Environment II-48

Transplant Center II-48

Organ Procurement Organization (OPO) II-48

Health Resources and Services Administration (HRSA) II-48

Division of Transplantation (DoT) II-48

United Network for Organ Sharing (UNOS) II-48

Organ Procurement and Transplantation Network (OPTN) II-48

University Renal Research and Education Association (URREA) II-48

Scientific Registry of Transplant Recipients (SRTR) II-49

Funding Sources II-49

Patient Education and Advocacy Organizations II-49

Legal Framework for Transplantation II-50

Legislation Covering Organ Transplant II-50

Organ Transplantation and Ethics II-50

Regulations Governing Artificial Organs II-51

9. Product Development/Innovations II-52

Pluristem Develops New Cell Graft for Cancer Patients II-52

CryoLife Develops Cryopreserved Orthopaedic Tissues Implants II-52

Japanese Innovators Develop New Prognostic Scoring Model for Liver Transplants II-52

EUREKA project E! 2674 MIDAS Develops New Test to Improve Graft Survival II-52

10. Recent Industry Activity II-53

St. Jude Medical's Heart Valve Obtains US FDA Approval II-53

Zimmer and Tutogen Expand Distribution Partnership II-53

Leman Cardiovascular Acquires Hancock Jaffe Laboratories II-53

Nabi Acquires Commercialization Rights of ATG-Fresenius S for North America II-53

Cytopia and Novartis Ink Research Collaboration and Global License Agreement II-54

ZLB Behring Inks Agreement with MedImmune II-54

Japanese Team To Perform Liver Transplants in Hyderabad II-54

Nabi Bags Approval for HB Intravenous in Liver Transplant Patients II-54

Schering-Plough Announces PROTECT study Initiation II-54

Allegheny General Hospital To Establish Adult Liver Transplantation Center in Oakland II-55

Global Hospitals to Setup an Organ Transplant Center in Kolkata II-55

GCC to Establish Organ Transplant Center II-55

Delhi-Based Hospital Offers Help in Setting Up of Liver Transplant Center in Lahore II-55

Kaiser To Shut Down Kidney Transplant Center II-55

Abiomed Obtains FDA Approval for Selling Artificial Hearts II-56

Astellas Bags FDA Approval to Use Prograf in Heart Transplant Patients II-56

New York State Department of Health Approves Program for Kidney Transplant for Queen's Community II-56

National Heart Institute Conducts First Double Lung Transplant in Malaysia II-56

The Netherlands Obtains Orphan Drug Designations for Treatment of DGF II-56

Papworth Transplants First Beating Human Heart in the UK II-56

Enzon to Return ATG-Fresenius S Rights to Fresenius Biotech II-57

Schering-Plough to Conduct 'PROTECT' Study II-57

Community Tissue Services Selects NOVA 2200 Supercritical Carbon Dioxide Sterilization Technology II-57

CryoLife Inks Agreement with The Magdi Yacoub Institute to Enhance Xenografts in Human Transplantation II-58

ReGen Inks Exclusive Marketing Deals with Polymedic and Xmedica II-58

University of California-Irvine Announces Closure of Liver- Transplantation Program II-58

Swedish Health Services Bags Approval for Liver Transplant Program II-59

New Organ Transplant Research Center in South Korea II-59

Child Lung Transplant Unit to be opened in Melbourne Hospital II-59

Narayana Hrudayalaya Health City Establishes Exclusive Organ Transplant Hospital II-59

Liver Transplant Facility in Delhi Region II-59

First Liver Transplant Research Institute in China II-59

PIMS to establish Liver Transplant Unit II-59

Liver Transplant Programme in Pakistan II-60

Isotechnika Gains FDA Approval II-60

FDA Offers Approval for Brain Stem Cell Transplant Trial II-60

Methodist Specialty and Transplant Hospital Gains Approval to Execute Liver Transplants II-60

Cubist Pharmaceuticals Enters into Licensing Agreement with XTL Biopharmaceuticals II-60

Jackson Memorial Receives Approval from the U.S. Centers for Medicare and Medicaid Services II-61

Royal Perth Hospital to Open Lung Transplant Unit in Perth II-61

Mater Hospital Opens Lung Transplant Unit in Dublin II-61

Genzyme Makes a Synergistic Purchase of Ilex Oncology II-61

NIAID Sets Up Clinical Consortium to Enhance Organ Transplants Success II-62

Chiron files NDA for Pulminiq Inhalation Solution II-62

Roche Acquires IL-15 Antagonist II-62

Genzyme Completes Acquisition of SangStat II-62

11. Focus on Select Global Players II-63

Abiomed Inc (USA) II-63

Arbios Systems, Inc. (USA) II-63

CryoLife, Inc.(USA) II-64

Exactech, Inc. (USA) II-64

Fresenius Medical Care AG & Co. KGaA (Germany) II-64

Forticell Bioscience, Inc. (USA) II-65

Gambro AB (Sweden) II-65

Genzyme Corporation (USA) II-65

Jarvik Heart, Inc. (USA) II-66

LifeCell Corporation (USA) II-66

Medtronic, Inc. (USA) II-67

MicroMed Cardiovascular, Inc. (USA) II-67

Organogenesis, Inc. (USA) II-67

SynCardia Systems (USA) II-68

Terumo Corporation (Japan) II-68

Thoratec Corporation (USA) II-68

Ventracor Limited (Australia) II-69

WorldHeart Corporation (USA) II-69

12. Global Market Perspective II-70

Table 1: World Recent Past, Current & Future Market Analysis for Organ Transplantation by Geographic Region - US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) II-70

Table 2: World 10-Year Perspective for Organ Transplantation by Geographic Region - Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) II-70

Table 3: World Recent Past, Current & Future Market Analysis for Heart Transplantation by Geographic Region - US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) II-71

Table 4: World 10-Year Perspective for Heart Transplantation by Geographic Region - Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) II-71

Table 5: World Recent Past, Current & Future Market Analysis for Kidney Transplantation by Geographic Region - US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) II-72

Table 6: World 10-Year Perspective for Kidney Transplantation by Geographic Region - Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) II-72

Table 7: World Recent Past, Current & Future Market Analysis for Liver Transplantation by Geographic Region - US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) II-73

Table 8: World 10-Year Perspective for Liver Transplantation by Geographic Region - Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) II-73

Table 9: World Recent Past, Current & Future Market Analysis for Pancreas Transplantation by Geographic Region - US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) II-74

Table 10: World 10-Year Perspective for PancreasTransplantation by Geographic Region - Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) II-74

Table 11: World Recent Past, Current & Future Market Analysis for Lung Transplantation by Geographic Region - US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) II-75

Table 12: World 10-Year Perspective for Lung Transplantation by Geographic Region - Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) II-75

Table 13: World Recent Past, Current & Future Market Analysis for Corneal Transplantation by Geographic Region - US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) II-76

Table 14: World 10-Year Perspective for Corneal Transplantation by Geographic Region - Percentage Breakdown of Number of Procedures for US, Canada, Europe, Asia (including Japan), Latin America and Rest of World Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) II-76

III. MARKET

1. The United States III-1

A.Market Analysis III-1

Current and Future Analysis III-1

Analysis by Value Sales III-1

Liver Transplantation Sustains Dominance III-1

Skin Grafts Take the Largest Chunk III-1

Analysis by Number of Procedures III-1

Intestine - Fastest Growing Segment III-1

Skin Grafts - Largest and Fastest Growing Tissue Segment III-2

Bone Graft Procedure Volume by Graft Type and Application III-2

US Organ Transplant Facts and Figures III-2

Number of Organ Transplants Witnesses Phenomenal Surge-2004 III-3

Increasing Organ Donations in New Jersey III-3

Innovative Means of Organ Procurement to Increase Organ Donations III-3

A New Technique to Enhance and Extend Kidney Transplants III-3

California Stands Up Against Insurance on HIV Patients' Transplantation III-4

Awareness Programs to Address Shortage of Minority Donors III-4

Organs and Tissues on A Recovery Spree III-4

Unexamined Human Tissue Transplants - A Major Threat III-5

Defective Medical Implants - A Health Hazard III-5

Eye Infections from Usage of MoistureLoc Leads to Corneal Transplants III-5

Sources of Donor Organs III-5

Table 15: US Kidney Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart) III-6

Table 16: US Liver Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart) III-6

Table 17: US Heart Donations by Cadaveric Donor Type for Years 2000 through 2005 (includes corresponding Graph/Chart) III-6

Table 18: US Lung Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart) III-7

Table 19: US Pancreas Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart) III-7

Table 20: US Intestine Donations by Donor Type - Cadaveric and Living for Years 2000 through 2005 (includes corresponding Graph/Chart) III-7

Lung Transplantation III-8

Lung Transplant Death Rates III-8

Heart-Lung Transplantation III-8

Incidence of Organ Transplants III-9

Table 21: Incidence of Organ Transplant Type for Kidney, Liver, Heart, Lung, Pancreas, Intestine, and Heart-Lung Transplants per 1 Million Population in the US for the Year 2000 through 2005 (includes corresponding Graph/Chart) III-9

Table 22: Incidence of Organ Transplants (Kidney, Liver, Heart, Lung, Pancreas, Intestine, and Heart-Lung) per 1 Million Population in the US by Recipient Race (White, African American, Asian, Hispanic, and Other) for 2005 (includes corresponding Graph/Chart) III-9

Table 23: Incidence of Organ Transplants (Kidney, Liver, Heart, Lung, Pancreas, Intestine, and Heart-Lung) per 1 Million Population in the US by Recipient Gender (Male, and Female) for 2005 (includes corresponding Graph/Chart) III-10

Table 24: Incidence of Organ Transplants (Kidney, Liver, Heart, Lung, Pancreas, Intestine, and Heart-Lung) per 1 Million Population in the US by Recipient Age (65+ Years, 50-64 Years, 35-49 Years, 18-34 Years, 11-17 Years, 6-10 Years, 1-5 Years, less than 1 Year) for 2005 (includes corresponding Graph/Chart) III-10

Waiting List III-11

Table 25: Waiting List of Patients As of July 2007 ( includes corresponding Graph/Chart) III-11

Table 26: Waiting List of Active and Inactive Patients for Years 2004 & 2005 (includes corresponding Graph/Chart) III-11 Waiting List for Heart Transplants III-12

Table 27: Waiting List of Active Patients for Heart for Years 2000 to 2005 (includes corresponding Graph/Chart) III-12

Categorized by Diseases III-12

Categorized by Age III-12

Categorized by Race III-12

Death Rates on Waiting List III-12

Kidney Transplantation Waiting List III-13

Categorized by Age III-13

Categorized by Race III-13

Waiting List for Liver Transplants III-13

Categorized by Age III-13

Categorized by Race III-13

Categorized by Gender III-13

Categorized by Diseases III-14

Categorized by Re-Transplant Necessity III-14

Death Rates on Waiting List III-14

Pancreas Transplant Waiting List III-14

Simultaneous Pancreas Kidney Transplantation Waiting List III-14

Pancreas After Kidney and Pancreas Transplant Alone Transplant Waiting List III-14

Waiting List for Lung Transplants III-14

Categorized by Age III-14

Categorized by Primary Diagnoses III-15

Categorized by Gender and Ethnic Makeup III-15

Waiting Time for Lung Transplant III-15

Annual Death Rates III-15

Waiting List for Intestine Transplants III-15

Death Rates on Waiting List III-16

Patient Survival Rate III-16

Table 28: Patient Survival Percent by Organ Type for 1-Year and 5-Years (includes corresponding Graph/Chart) III-16

Annual Death Rate of Kidney Recipients III-17

Pancreas Patient Survival Rate III-17

Pancreas Graft Survival Rate III-17

Immunosuppression Therapy III-17

Immunosuppression Therapy for Heart Transplant Recipients III-17

Table 29: Usage Rates of Major Immunosuppressants in 2004 (includes corresponding Graph/Chart) III-17

Immunosuppression Therapy for Kidney Transplant Recipients III-18

Immunosuppression Therapy for Pancreas Transplants III-18

Immunosuppression Therapy for Lung Transplant Recipients III-18

Table 30: Usage Rates of Induction Therapies in 2005 (includes corresponding Graph/Chart) III-18

Immunosuppression Therapy Following Bone Marrow Transplantation III-19

Table 31: US Recent Past, Current & Future Market Analysis for Immunosuppressive Drug Therapy Following Bone Marrow Transplantation by Category - For GVHD and Maintenance Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2012 (includes corresponding Graph/Chart) III-19

Immunosuppression Therapy Following Blood Stem Cell Transplantation III-19

Table 32: US Recent Past, Current & Future Market Analysis for Immunosuppressive Drug Therapy Following Blood Stem Cell Transplantation by Category - For GVHD and Maintenance Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2012 (includes corresponding Graph/Chart) III-20

United Network for Organ Sharing III-20

The American Association of Tissue Banks (AATB) III-20

Accredited Banks from Select US States III-21

Eye Banks from Select US States III-22

Number of Transplant Center Programs III-23

Table 33: Number of Transplant Center Programs for the Years 1990, 1997 and 2000 (includes corresponding Graph/Chart) III-24

Table 34: Average Number of Transplants Per Program for the Years 1990, 1997 and 2000 (includes corresponding Graph/Chart) III-24

Strategic Developments III-24

Select Players III-30

Abiomed Inc III-30

Arbios Systems Inc. III-31

Arrow International, Inc. III-31

CryoLife, Inc. III-32

Exactech, Inc. III-32

Genzyme Corporation III-33

Jarvik Heart Inc. III-33

LifeCell Corporation III-33

Medtronic Inc III-34

MicroMed Cardiovascular, Inc. III-34

Organogenesis Inc III-35

Forticell Bioscience, Inc. III-35

SynCardia Systems III-35

Thoratec Corporation III-35

WorldHeart Corporation III-36

B.Market Analytics III-37

Table 35: US Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type - Heart, Kidney, Liver, Pancreas, Lung and Intestine Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2012 (includes corresponding Graph/Chart) III-37

Table 36: US 10-Year Perspective for Organ Transplantation by Organ Type - Percentage Breakdown of Dollar Sales for Heart, Kidney, Liver, Pancreas, Lung and Intestine Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-38

Table 37: US Recent Past, Current & Future Market Analysis for Tissue Transplantation by Tissue Type - Cornea, Heart Valves and Skin Grafts Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2012 (includes corresponding Graph/Chart) III-39

Table 38: US 10-Year Perspective for Tissue Transplantation by Tissue Type - Percentage Breakdown of Dollar Sales for Cornea, Heart Valves and Skin Grafts Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-39

Table 39: US Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type - Heart, Kidney, Liver, Pancreas, Lung and Intestine Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-40

Table 40: US 10-Year Perspective for Organ Transplantation by Organ Type - Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas, Lung and Intestine Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-41

Table 41: US Recent Past, Current & Future Market Analysis for Tissue Transplantation by Tissue Type - Cornea, Heart Valves, Skin Grafts, Vascular Grafts, Bone Marrow and Bone Grafts Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-42

Table 42: US 10-Year Perspective for Tissue Transplantation by Tissue Type - Percentage Breakdown of Number of Procedures for Cornea, Heart Valves, Skin Grafts, Vascular Grafts, Bone Marrow and Bone Grafts Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-42

Table 43: US Recent Past, Current & Future Market Analysis for Bone Graft Transplantation by Graft Type - Autologous Graft, Allograft and Other Materials Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-43

Table 44: US 10-Year Perspective for Bone Graft Transplantation by Graft Type - Percentage Breakdown of Number of Procedures for Autologous Graft, Allograft and Other Materials Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) (includes corresponding Graph/Chart) III-43

Table 45: US Recent Past, Current & Future Market Analysis for Bone Graft Transplantation by Application - General Orthopedics, Spinal Fusions and Cranio/Maxillofacial Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-44

Table 46: US 10-Year Perspective for Bone Graft Transplantation by Application - Percentage Breakdown of Number of Procedures for General Orthopedics, Spinal Fusions and Cranio/Maxillofacial Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-44

2. Canada III-45

A.Market Analysis III-45

Current and Future Analysis III-45

Canadians More Receptive to Organ Transplants III-45

Waiting List III-45 Table 47: Canadian Patients (Active and Inactive) on Waiting List by Organ Type for 2005 & 2006 (includes corresponding Graph/Chart) III-46

Organ Donation III-46

Success Rate of Organ Transplants III-46

Table 48: Success Rate of Organ Transplants After 1-Year (includes corresponding Graph/Chart) III-46

Strategic Development III-46

B.Market Analytics III-47

Table 49: Canadian Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type - Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-47

Table 50: Canadian 10-Year Perspective for Organ Transplantation by Organ Type - Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-48

3. Europe III-49

A.Market Analysis III-49

Current and Future Analysis III-49

Italy III-49

Surge in Organ Transplants III-49

The United Kingdom III-49

Organ and Tissue Transplantation in the UK III-49

Table 51: UK Organ Transplantations for the Years 2003 and 2004 (includes corresponding Graph/Chart) III-49

Table 52: Waiting List (Active and Inactive) by Organ Type in the UK for the Years 2003 and 2004 (includes corresponding Graph/Chart) III-50

Kidney Transplantation III-50

Waiting List III-50

Categorized by Race III-50

Categorized by Age and Sex III-50

Donors and Transplantation Recipients III-50

Categorized by Race III-51

Categorized by Age and Gender III-51

Pancreas Transplantation III-51

Waiting List III-51

Categorized by Race III-51

Categorized by Age and Gender III-51

Donors and Transplantations III-51

Categorized by Race III-51

Categorized by Age and Gender III-51

Lung Transplant Record Numbers Boasts of Lung Power III-52

Bladder Transplantation A Roaring Success III-52

Russia III-52

Organ Transplantations Show a Downward Trend in Russia III-52

Turkey III-52

Akdeniz University - A World-Renowned Transplantation Center III-52

Strategic Developments III-53

Select Players III-54

Fresenius Medical Care AG & Co. KGaA (Germany) III-54

Gambro AB (Sweden) III-54

B.Market Analytics III-55

Table 53: European Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type - Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-55

Table 54: European 10-Year Perspective for Organ Transplantation by Organ Type - Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-56

4. Asia III-57

A.Market Analysis III-57

Current & Future Analysis III-57

Australia III-57

Australia Registers Highest Success Rate in Transplantation III-57

Kidney Transplantation Snapshots III-57

Organ Donor Register III-57

China III-58

Organ Transplantations in China III-58

Transplantation Tourism in China III-58

Low Transplant Success Rate Due to Unskilled Professionals III-58

Cost Effective Transplant Procedures Lure Foreign Patients III-58

Illegal Activities for Harvesting Organs in China III-59

Regulations on Organ Transplantation III-59

Regulations on Brain Death III-60

India III-60

Overview of Renal Transplantation III-60

Transplantation Expenses in India III-60

Indian Government to amend Organ Transplantation Rules III-60

Singapore III-61

Awareness Programs to Increase Living Kidney Donations in Singapore III-61

Taiwan III-61

Taiwan Competes with the US in Kidney and Liver Transplant Survival Rates III-61

Strategic Developments III-61

Select Players III-64

Terumo Corporation (Japan) III-64

Ventracor Limited (Australia) III-64

B.Market Analytics III-65

Table 55: Asia Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type - Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-65

Table 56: Asia 10-Year Perspective for Organ Transplantation by Organ Type - Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-66

5. Latin America III-67

A.Market Analysis III-67

Current & Future Analysis III-67

Brazil - A Major Transplant Market III-67

B.Market Analytics III-67

Table 57: Latin America Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type - Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-67

Table 58: Latin America 10-Year Perspective for Organ Transplantation by Organ Type - Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-68

6. Rest of World III-69

A.Market Analysis III-69

Current & Future Analysis III-69

Kuwait - A Rapidly Emerging 'Third World' Country in Organ Transplants III-69

Strategic Development III-69

B.Market Analytics III-70

Table 59: Rest of World Recent Past, Current & Future Market Analysis for Organ Transplantation by Organ Type - Heart, Kidney, Liver, Pancreas and Lung Independently Analyzed by Number of Procedures for Years 2003 through 2012 (includes corresponding Graph/Chart) III-70

Table 60: Rest of World 10-Year Perspective for Organ Transplantation by Organ Type - Percentage Breakdown of Number of Procedures for Heart, Kidney, Liver, Pancreas and Lung Markets for Years 2003, 2007 & 2012 (includes corresponding Graph/Chart) III-71

IV. COMPETITIVE LANDSCAPE

To order this report:

World Organ And Tissue Transplantation Market

More market research reports here!

Contact Information